Cinaciguat is the first of a class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Cinaciguat at 10 μM substantially boosts the production of intracellular cGMP, yet shows no dose-dependent impacts on cell contraction or calcium transient changes[2]. |
体内研究 | Administering Cinaciguat at a dose of 10 mg/kg/day orally to diabetic rats does not alter blood glucose levels, however, it reduces water consumption. Cinaciguat treatment also mitigates oxidative stress related to diabetes mellitus, protects against alterations in the NO-sGC-cGMP-PKG pathway, and reduces myocardial hypertrophy and apoptosis associated with diabetes mellitus[1]. Cinaciguat at concentrations of 1, 10, and 100 nM elicits concentration-dependent relaxations in gastrointestinal smooth muscle strips from both WT and apo-sGC mice, although it does not affect phasic activity caused by PGF2α in these muscle strips[3]. |
体外研究 | Cinaciguat at 10 μM substantially boosts the production of intracellular cGMP, yet shows no dose-dependent impacts on cell contraction or calcium transient changes[2]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.77mL 0.35mL 0.18mL |
8.84mL 1.77mL 0.88mL |
17.68mL 3.54mL 1.77mL |
CAS号 | 329773-35-5 |
分子式 | C36H39NO5 |
分子量 | 565.699 |
别名 | BAY 58-2667 |
运输 | 蓝冰 |
存储条件 |
粉末 Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 50 mg/mL(88.39 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |